Cell Point (India) Ltd

As of 19-Nov, Cell Point (India) Ltd's stock price is at 17.25, down 2.82%, and has significantly underperformed its sector and the Sensex. The stock is trading below all major moving averages, with a notable decline in delivery volume and a year-to-date drop of 35.51%, indicating negative investor sentiment.

As of November 14, 2025, Cell Point is considered overvalued with a PE ratio of 98.49, significantly higher than its peers, and despite a recent one-week return of 8.33%, it has declined 27.1% year-to-date, indicating it is not a favorable investment at its current price.

As of November 14, 2025, Cell Point is considered overvalued with a PE ratio of 98.49 and a year-to-date return of -27.1%, significantly underperforming compared to its peers and the Sensex.

As of November 14, 2025, Cell Point is considered overvalued with a PE ratio of 98.49, significantly higher than peers like PTC India and Elitecon International, and despite a recent 8.33% price increase, it has underperformed the Sensex with a year-to-date decline of 27.1%.

As of 13-Nov, Cell Point (India) Ltd's stock price is 18.65, up 1.08%, but it has seen a significant decline in investor participation and a year-to-date drop of 30.28%. Despite recent short-term gains, the stock has underperformed over the longer term compared to the broader market.

Cell Point has shown consistent growth in net sales, reaching 324.71 Cr in March 2025, but profitability metrics have fluctuated, with operating profit declining from 19.34 Cr in March 2023 to 8.88 Cr in March 2025. Total assets increased to 137.69 Cr in March 2025, while cash flow improved to 0.00 Cr, indicating ongoing liquidity challenges.

As of November 6, 2025, Cell Point is considered overvalued with a high PE ratio of 91.67 and a low ROCE of 3.63%, significantly underperforming against the Sensex and its peers, indicating a shift in valuation from fair to expensive.

As of November 3, 2025, Cell Point is fairly valued with a PE ratio of 90.91, an EV to EBITDA of 9.88, and a Price to Book Value of 0.45, contrasting with peers like Elitecon International and PTC India, while also showing a -44.62% return over the past year compared to the Sensex's 6.00%.

As of October 31, 2025, Cell Point is considered overvalued with a PE Ratio of 90.66 and disappointing stock performance, significantly underperforming its peers and the Sensex.

As of October 31, 2025, Cell Point is considered overvalued with a PE Ratio of 90.66, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -32.9%.

As of October 31, 2025, Cell Point is considered overvalued with a PE ratio of 90.66 and a year-to-date return of -32.9%, contrasting sharply with its peers and indicating it may not be a sound investment at its current price.

As of 23-Oct, Cell Point (India) Ltd is currently priced at 17.75, reflecting a 2.31% increase today; however, it has significantly underperformed over the longer term with declines of 2.47% in the past week and 33.64% year-to-date. The stock is trading below all major moving averages, indicating a bearish trend, and has seen a notable drop in investor interest.

As of October 16, 2025, Cell Point is fairly valued with a PE ratio of 91.92, an EV to EBITDA of 9.93, and a Price to Book Value of 0.46, making it competitively priced compared to peers despite a year-to-date stock underperformance of -31.96% against the Sensex's 8.21% return.

As of October 14, 2025, Cell Point is considered overvalued with a high PE ratio of 94.95, low Price to Book Value of 0.47, and poor performance indicators, resulting in a significant year-to-date return of -29.72% compared to the Sensex's 6.35%.

As of October 1, 2025, Cell Point is fairly valued with a PE ratio of 33.91, lower than peers like Elitecon International and MMTC, but has underperformed against the Sensex with a year-to-date return of -32.15%.

As of October 1, 2025, Cell Point is fairly valued with a PE ratio of 33.91, despite a year-to-date stock decline of -32.15%, contrasting with the Sensex's positive return of 5.04%.

As of 24-Sep, Cell Point (India) Ltd is priced at 18.75, showing no change and a 0.00% movement. The stock has underperformed year-to-date and over the past year, despite some short-term gains, indicating a negative long-term trend.

As of September 23, 2025, Cell Point's valuation has shifted to fair, with a PE Ratio of 36.16, an EV to EBIT of 18.29, and a Price to Book Value of 0.49, underperforming the market with a year-to-date return of -29.91% compared to the Sensex's 6.45% gain.

As of 23-Sep, Cell Point (India) Ltd's stock price is at 18.75, with a slight increase of 0.27%. Despite recent short-term gains, the stock has a negative year-to-date performance of -29.91% and a one-year return down by 42.13%, indicating ongoing challenges in investor confidence.